Genmab — Maj 2015
-
The Scottish Medicines Consortium (SMC) has accepted seven new medicines for use in NHS Scotland. Two of these medicines, ofatumumab (Azerra) for the treatment of chronic lymphocytic leukaemia (CLL) and idelalisib (Zydelig) for the treatment of follicular lymphoma,
-
Ofatumumab also gives clinicians a wider choice and the ability to tailor therapy to individual patients. SMC restricted its use to those patients who would not be considered for treatment with bendamustine, and who would receive chlorambucil-based therapy.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind